{
  "documents": [
    {
      "id": "cluster_4_doc1",
      "content": "PriorityHealth memo dated 2023-11-07: Patient Evelyn Torrence (ID# PH-7284-J) underwent a second round of immunotherapy at Lakeside Oncology Center following initial positive response. Treatment regimen includes pembrolizumab every 3 weeks. Research division notes connection to ongoing IMPACT-09 trial evaluating rare histiocytic disorders.",
      "metadata": {
        "format": "insurance_memo"
      }
    },
    {
      "id": "cluster_4_doc2",
      "content": "Provider report from Dr. Alvaro Mendoza: 68-year-old patient presenting with Erdheim-Chester disease (PH-7284-J) showed 40% tumor reduction post-6 cycles. Next genomic sequencing scheduled January 15th at Northwestern Precision Medicine Hub under research grant GNM-2280.",
      "metadata": {
        "format": "provider_report"
      }
    },
    {
      "id": "cluster_4_doc3",
      "content": "Policy update effective February 1st: CAR-T therapies requiring prior auth will now be expedited for rare hematopoietic conditions. Impacts patients at 14 designated centers including Lakeside Oncology. Requires tertiary pathology review and EOC committee approval (reference: PHX-9901B).",
      "metadata": {
        "format": "policy_document"
      }
    },
    {
      "id": "cluster_4_doc4",
      "content": "Chicago Tribune health section article (December 2023): Northwestern Medicine pioneering new dual-targeted therapy approach for histiocytosis patients. Mentions ongoing IMPACT-09 trial coordinator Dr. Rajiv Varma and 68-year-old participant achieving partial remission.",
      "metadata": {
        "format": "news_article"
      }
    }
  ],
  "metadata": {
    "category": "cluster",
    "cluster_id": "cluster_4",
    "cluster_risk": "HIGH",
    "content_summary": "Patient's journey with rare histiocytic disorder through specialized immunotherapy treatment, connected to research trial and policy changes for advanced therapies.",
    "person": {
      "entities": [
        [
          "Evelyn Torrence",
          "NAME"
        ],
        [
          "PH-7284-J",
          "PATIENT_ID"
        ],
        [
          "68-year-old",
          "AGE"
        ],
        [
          "Erdheim-Chester disease",
          "MEDICAL_CONDITION"
        ],
        [
          "pembrolizumab",
          "TREATMENT"
        ],
        [
          "Lakeside Oncology Center",
          "PROVIDER"
        ],
        [
          "Northwestern Precision Medicine Hub",
          "PROVIDER"
        ],
        [
          "IMPACT-09 trial",
          "EVENT"
        ],
        [
          "Dr. Alvaro Mendoza",
          "PROVIDER"
        ],
        [
          "Dr. Rajiv Varma",
          "PROVIDER"
        ],
        [
          "GNM-2280",
          "NON_PERSONAL_ID"
        ],
        [
          "PHX-9901B",
          "NON_PERSONAL_ID"
        ],
        [
          "2023-11-07",
          "EVENT_DATE"
        ],
        [
          "January 15th",
          "EVENT_DATE"
        ],
        [
          "December 2023",
          "EVENT_DATE"
        ]
      ]
    },
    "questions": [
      {
        "q": "What rare condition and treatment response percentage were documented for patient PH-7284-J?",
        "a": "Erdheim-Chester disease with 40% tumor reduction post-6 cycles.",
        "sources": [
          "cluster_4_doc2"
        ],
        "type": "specific"
      },
      {
        "q": "What new policy requirement affects CAR-T therapy approvals for rare blood conditions effective February?",
        "a": "Requires tertiary pathology review and EOC committee approval.",
        "sources": [
          "cluster_4_doc3"
        ],
        "type": "general"
      },
      {
        "q": "Which two providers and research trial are associated with Evelyn Torrence's immunotherapy treatment?",
        "a": "Dr. Alvaro Mendoza, Dr. Rajiv Varma, and IMPACT-09 trial.",
        "sources": [
          "cluster_4_doc2",
          "cluster_4_doc4"
        ],
        "type": "specific"
      },
      {
        "q": "Which facility performs advanced genomic sequencing for histiocytosis patients, and what therapy approach was highlighted in the news article?",
        "a": "Northwestern Precision Medicine Hub; news reported a dualâ€‘targeted therapy approach for histiocytosis.",
        "sources": [
          "cluster_4_doc2",
          "cluster_4_doc4"
        ],
        "type": "general"
      }
    ]
  }
}